Spondyloarthritis Research and Treatment Network 23rd SPARTAN Annual Meeting 2025

1. Overview
The Spondyloarthritis Research and Treatment Network 23rd SPARTAN Annual Meeting 2025 provides an in-depth review of the latest advancements in the diagnosis, pathophysiology, and treatment of Spondyloarthritis (SpA). The program covers fundamental mechanisms like HLA-B27, cutting-edge therapies such as CAR-T, evolving imaging guidelines, and critical intersections with conditions like Inflammatory Bowel Disease (IBD).
Course Date: May 9-10, 2025
2. Learning Objectives

Analyze the pathophysiological mechanisms of Spondyloarthritis, including the roles of HLA-B27, T cells, and spatial gene profiles.

Evaluate individualized treatment options and the safety of emerging therapies like CAR-T and NSAIDs in adult and pediatric SpA patients.

Apply advanced MRI protocols and physical exam techniques to accurately diagnose and monitor radiographic progression in axial SpA.

Assess the latest ACR-SPARTAN-SAA clinical guidelines and outcome measures, such as BASDAI, in managing psoriatic arthritis and SpA.

Identify the unique clinical manifestations, sex-gender differences, and comorbidities, particularly Inflammatory Bowel Disease, associated with SpA.

3. Target Audience

Best for rheumatologists and immunologists who want updates on spondyloarthritis pathophysiology, advanced imaging, and targeted therapies.

4. Topics

Day 1 Classification and Clinical Manifestation of SpA- Deep Dive into IBP – Soha Dolatabadi, MD

Day 1 Disease Mechanisms in SpA- With and Without HLAB27 – Akihiro Nakamura, MD, PhD

Day 1 IBD and SpA – Reem Jan, MD, MBBS

Day 1 Individualize axSpA Treatment Options a Case Based Discussion- Lianne Gensler, MD

Day 1 MRI Workshop- Protocol, Finding, and Mimickers – Dennis Poddubnyy, MD, PhD, MSc

Day 1 Sex-Gender differences in Presentation and Manifestations of SpA – Lihi Eder, MD, PhD

Day 1 Slowing Radiographic Progression in Axial SpA – Marina Magrey, MD

Day 1 SpA Physical Exam Workshop – Philip Mease, MD

Day 2 Basic Science – Ruth Napier, PhD

Day 2 CAR-T (non-CD19) – Naoto Hirano, MD, PhD

Day 2 CLASSIC – Walter Maksymowych, MD, FRCP, FACP, University of Alberta, Alberta

Day 2 Clinical Science and Imaging – Jean Liew, MD, MS

Day 2 Clinical Trials – Abhijeet Danve, MBBS, MD, FACP

Day 2 IBD and SpA – Reem Jan, MD, MBBS

Day 2 Neuroimaging of Pain in Ankylosing Spondylitis Karen D. Davis, PhD, FCAHS, FRSC, Professor, Department of Surgery …

Day 2 SESSION I- Year in Review Moderators- Nigil Haroon, MD and Mohamed Bittar, MD

Day 2 SPARTAN Research Career Achievement and Distinguished Service Award Presentations

Day 2 T cells Animal Studies CD4-CD8-MAIT-NK-T – Judith Smith, MD, PhD

Day 2 T cells AS Patients – Michael Paley, MD, PhD

Day 3 ACR-SPARTAN-SAA Guidelines – Liron Caplan, MD, PhD

Day 3 BASDAI and its Components as Outcome Measures for axPsA – Pankti Mehta, MD, MBBS

Day 3 BASIS – Sibel Aydin, MD

Day 3 Imaging – Denis Poddubnyy, MD, PhD, MSc

Day 3 Mapping the PBR of SpA-associated Versus SpA-neutral HLA-B-27 Alleles, Using a High-throughput Genetic Screening …

Day 3 MRI neg axSpA does not exist – Lianne Gensler, MD, Atul Deodhar, MD

Day 3 New Pediatric SpA Classification Criteria – Pamela Weiss, MD, MSCE

Day 3 Safety of Prescription NSAIDs in Adults with IBD- Data from a Large Administrative Claims Cohort – Adam Mayer, MD

Day 3 Serum Proteomic Analysis of Cellular Immune Clusters in Psoriatic Arthritis – Steven Dang

Day 3 Spatial Gene Profiles for New Bone Formation in Ankylosing Spondylitis – Akihiro Nakamura, MD, PhD

Day 3 The Deubiquitinase TRABID is a Novel Therapeutic Target in Spondyloarthritis – Archita Srinath

Day 3 The Relationship Between HLA-B27 Positivity and Inflammatory Back Pain in the US Population – Mark Hwang, MD

Group Day 1

Group Day 2